This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Renal Diseases  • Dialysis  • Randomized Controlled Trial  • Alert me on articles by topic

Mike Mitka

JAMA. 2007;298(17):1995-1996.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A costly and widely used medication for patients on hemodialysis is no better at reducing mortality than lower-cost alternatives, according to the findings of a new study.

In the largest prospective randomized study to date comparing patients on hemodialysis who were given sevelamer hydrochloride (Renagel, Genzyme Corporation, Cambridge, Mass) or a calcium-based binder to treat hyperphosphatemia, the Dialysis Clinical Outcomes Revisited (DCOR) trial, researchers found that all-cause mortality was the same in the group taking sevelamer (267 deaths) and the group taking a calcium-based binder (275 deaths) (Suki WN et al. Kidney Int. doi:10.1038/sj.ki.5002466 [published online ahead of print August 29, 2007]).

Maintaining appropriate levels of phosphate is important for patients on hemodialysis, but the best way to do so remains open to debate. (Photo credit: AJPhoto/www.sciencesource.com)

However, in a prespecified secondary analysis of the trial (which was sponsored by Genzyme), the researchers did find . . . [Full Text of this Article]

GETTING RID OF PHOSPHATE